8-K: Silexion Therapeutics Enacts 1-for-10 Reverse Stock Split

Silexion Therapeutics Corp implemented a 1-for-10 reverse share split and adjusted warrants to maintain Nasdaq listing compliance.

Summary

• Silexion Therapeutics Corp (SLXN) completed a 1-for-10 reverse share split of its ordinary shares, effective after the close of trading on May 28, 2026.
• The primary purpose of the reverse share split is to maintain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
• As a result of the split, the number of issued and outstanding ordinary shares decreased by a 1-for-10 ratio, and the par value per share increased from $0.0135 to $0.135.
• The company's authorized share capital remains at $796,500, now consisting of 5,900,000 ordinary shares, down from 59,000,000.
• Warrants exercisable for ordinary shares were also adjusted: each pre-split warrant now entitles the holder to 1/10th of an ordinary share, and the exercise price increased ten-fold to $15,525.00 per post-Reverse Share Split ordinary share.
• Fractional shares resulting from warrant exercises will be rounded up to the nearest whole number of ordinary shares at the broker level.
• Ordinary shares began trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol SLXN at market open on May 29, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a necessary defensive move to maintain listing, which is positive for continued market access. However, it does not address underlying operational or financial performance issues, which typically drive long-term value, hence the neutral-to-slightly-negative sentiment.

Positives

• The reverse share split allows Silexion Therapeutics to maintain its listing on the Nasdaq Capital Market, preserving access to public capital markets and liquidity for shareholders.
• Warrant holders will benefit from fractional shares being rounded up to the nearest whole number upon exercise, which is a favorable adjustment.

Negatives

• A reverse stock split often signals a company's struggle with a low share price, which can reflect underlying operational or financial challenges.
• The significant increase in the warrant exercise price to $15,525.00 per share may deter warrant holders from exercising, potentially reducing future capital inflow from warrant exercises.

Risks

• There is an inherent risk that the reverse share split may not sustainably increase the share price above Nasdaq's minimum bid requirement, potentially leading to future delisting concerns.
• The reverse split does not address the fundamental reasons for the low share price, and the stock may continue to decline if business performance does not improve.

Future Outlook

The filing primarily details a completed corporate action and does not provide explicit forward-looking statements or guidance beyond the immediate effect of the reverse share split on trading and warrant terms. The action itself is a forward-looking measure intended to ensure continued Nasdaq listing compliance.

Management Comments

• Ms. Mirit Horenshtein Hadar, CFO, is available for questions via email at mirit@silexion.com.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategic maneuver, particularly for small-cap companies in the biotechnology sector, to meet minimum bid price requirements for continued listing on major exchanges like Nasdaq. This action aims to improve the stock's perception, enhance liquidity, and potentially attract institutional investors, although it does not fundamentally alter the company's market capitalization or underlying business operations.

Comparison to Industry Standards

• Reverse stock splits are a standard corporate action for companies facing delisting from exchanges like Nasdaq due to low share prices, aligning Silexion's move with common industry practice.
• Many small-cap biotech companies, such as TherapeuticsMD (TXMD) or Sorrento Therapeutics (SRNEQ), have executed similar reverse splits to maintain compliance, often with varying degrees of long-term success in share price recovery.
• The 1-for-10 ratio is a common magnitude for such splits, aiming for a significant price increase to comfortably exceed minimum bid requirements.
• The proportional adjustment of warrants is also standard practice to ensure the economic terms of the warrants remain consistent with the underlying shares post-split.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares held by each shareholder decreased by a 1-for-10 ratio. While the per-share price is expected to increase proportionally, the total value of holdings should remain the same immediately after the split. The action aims to prevent delisting, preserving the ability to trade on Nasdaq.
• Warrant Holders: The number of ordinary shares exercisable per warrant decreased by 1-for-10, and the exercise price increased ten-fold. The rounding up of fractional shares upon exercise is a beneficial adjustment for warrant holders.
• Nasdaq: The action aims to maintain compliance with Nasdaq's listing requirements, benefiting the exchange by upholding its standards and avoiding a delisting event.

Next Steps

• Continued trading of Silexion Therapeutics Corp's ordinary shares on the Nasdaq Capital Market under the existing ticker symbol SLXN on a split-adjusted basis.
• Continued trading of the company's warrants under the existing ticker symbol SLXNW.

Key Dates

Recommendation

The reverse stock split is a technical maneuver to maintain Nasdaq listing, not an indicator of improved business fundamentals. While it removes an immediate delisting threat, it doesn't inherently create value. Investors should hold to observe if the company can leverage its continued listing to improve its operational performance and attract new investment, rather than reacting solely to the cosmetic change in share price.

Keywords

Silexion Therapeutics, SLXN, Reverse Stock Split, Warrant Adjustment, Nasdaq Listing, Share Consolidation, Corporate Action, Biotechnology, Capital Markets